BioSpace News Archive

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29

Transaction Adds Hospice Services through 21 Locations Across Six States, Producing Annualized Revenue of Approximately $55 Million

Results Support Ongoing Phase 2 ELEVATE 1 Study in Pulmonary Arterial Hypertension

Protagonist Therapeutics, Inc. announced that abstracts providing data from the PN-943 and PTG-200 clinical programs have been accepted for poster presentations at upcoming scientific conferences.

T cell receptor (TCR) T cell therapy targeting HA-1 expressing tumors designed to manage post-hematopoietic stem cell transplant leukemic relapse

Tmunity Therapeutics, Inc. announced it has entered into an exclusive license and research collaboration agreement with Children’s Hospital of Philadelphia to advance a glypican 2 chimeric antigen receptor T-cell therapy for the treatment of neuroblastoma, a rare cancer that affects the developing nervous system.

Leading depression treatment provider aligns with NeuroStar® Advanced Therapy patients to share empowering personal stories and fight mental health stigma

Bay Labs, a growing medical technology company applying deep learning technology to emulate the expertise of highly-trained medical experts, announced today that it has achieved a number of significant milestones, including renaming the company to Caption Health, effective immediately.

Lipocine Inc. announced that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease will be presented at The Liver Meeting® 2019.

Chronometriq, the Montreal-based provider of access-to-care and patient engagement tools, announced that the company has secured more than $20 million CAD in Series B funding.